https://clinicaltrials.gov/ct2/show/NCT03624062
MER3101: MAS-1 Adjuvanted Antigen-specific Immunotherapeutic for Prevention and Treatment of Type 1 Diabetes (MER3101)
Study Type : Interventional
Estimated Enrollment : 28 participants
Allocation: Randomized
Intervention Model: Sequential Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: MER3101: MAS-1 Adjuvanted Antigen-specific Immunotherapeutic for Prevention and Treatment of Type 1 Diabetes
Estimated Study Start Date : January 2019
Estimated Primary Completion Date : April 4, 2022
Estimated Study Completion Date : April 4, 2022
